Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics logo

About Medicenna Therapeutics Stock (NASDAQ:MDNA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$0.39
52-Week Range
N/A
Volume
1.27 million shs
Average Volume
160,047 shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Consensus Rating
Buy

Company Overview

Medicenna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

MDNA MarketRank™: 

Medicenna Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 798th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Medicenna Therapeutics has received no research coverage in the past 90 days.

  • Read more about Medicenna Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.17) to ($0.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medicenna Therapeutics is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for MDNA.
  • Dividend Yield

    Medicenna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Medicenna Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MDNA.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Medicenna Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.38% of the stock of Medicenna Therapeutics is held by institutions.

  • Read more about Medicenna Therapeutics' insider trading history.
Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas.
See More Headlines

MDNA Stock Analysis - Frequently Asked Questions

Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), e.l.f. Beauty (ELF), Meta Platforms (META), Arista Networks (ANET) and AppLovin (APP).

Company Calendar

Last Earnings
11/12/2021
Today
8/02/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MDNA
CIK
1807983
Employees
16
Year Founded
N/A

Price Target and Rating

High Price Target
$2.50
Low Price Target
$2.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.60 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.68%
Return on Assets
-35.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.57
Quick Ratio
9.57

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
69,637,000
Free Float
46,587,000
Market Cap
$10.93 million
Optionable
Not Optionable
Beta
1.30
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:MDNA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners